S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer.

Background Increased expression of S100A6 in many cancer tissues and its association with tumor behavior and patient prognosis were demonstrated, and there are no studies analyzing the serum levels of S100A6 in patients with gastric cancer (GC).